PhRMA says enforcing patent rights is “absolutely essential” in response to senate bill

30 April 2015

A US bipartisan senate group has released a new patent reform bill to address abusive patent litigation.

The Protecting American Talent and Entrepreneurship (PATENT) Act was led by Senate Judiciary Committee Chairman Chuck Grassley (R-IA), Ranking Member Patrick Leahy (D-VT), Senator John Cornyn (R-TX), and Senator Chuck Schumer (D-NY).

The Pharmaceutical Research and Manufacturers of America (PhRMA) welcomed the bill but senior vice president Robert Zirkelbach said: “While the Senate legislation is an improvement over the House version, there continue to be issues of concern that intellectual property holders have raised, and we look forward to working with Senators to address those concerns."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >